MA32095B1 - Inhibiteurs d'aldh-2 dans le traitement d'une accoutumance - Google Patents
Inhibiteurs d'aldh-2 dans le traitement d'une accoutumanceInfo
- Publication number
- MA32095B1 MA32095B1 MA33106A MA33106A MA32095B1 MA 32095 B1 MA32095 B1 MA 32095B1 MA 33106 A MA33106 A MA 33106A MA 33106 A MA33106 A MA 33106A MA 32095 B1 MA32095 B1 MA 32095B1
- Authority
- MA
- Morocco
- Prior art keywords
- aldh
- addiction
- inhibitors
- treatment
- amphetamines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2008/051862 WO2009094028A1 (en) | 2008-01-24 | 2008-01-24 | Aldh-2 inhibitors in the treatment of addiction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32095B1 true MA32095B1 (fr) | 2011-02-01 |
Family
ID=39731733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33106A MA32095B1 (fr) | 2008-01-24 | 2010-08-23 | Inhibiteurs d'aldh-2 dans le traitement d'une accoutumance |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2254878A1 (de) |
| JP (1) | JP2011510072A (de) |
| KR (1) | KR20100130589A (de) |
| CN (1) | CN101925590A (de) |
| AU (1) | AU2008348372A1 (de) |
| BR (1) | BRPI0822129A2 (de) |
| CA (1) | CA2712750A1 (de) |
| EC (1) | ECSP10010417A (de) |
| IL (1) | IL207127A0 (de) |
| MA (1) | MA32095B1 (de) |
| MX (1) | MX2010008111A (de) |
| WO (1) | WO2009094028A1 (de) |
| ZA (1) | ZA201004671B (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102161648A (zh) * | 2011-02-18 | 2011-08-24 | 中国药科大学 | 具有选择性雌激素受体调节活性的异黄酮类化合物的制备方法及其用途 |
| TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
| TWI468403B (zh) * | 2011-08-30 | 2015-01-11 | Gilead Sciences Inc | 用於治療成癮之ａｌｄｈ－２抑制劑 |
| EP3697415A4 (de) * | 2017-10-16 | 2021-07-14 | Amygdala Neurosciences, Inc. | Kombinationstherapie zur verhinderung von sucht |
| CN108276374B (zh) * | 2018-03-29 | 2020-01-31 | 天津科技大学 | 黄酮类芳香化酶抑制剂及其制备方法与应用 |
| CN110922394B (zh) * | 2019-11-21 | 2021-04-06 | 中国科学院宁波材料技术与工程研究所 | 一种基于天然黄酮类化合物的生物基本征阻燃环氧树脂前驱体及其制备方法和应用 |
| WO2023235753A2 (en) * | 2022-05-31 | 2023-12-07 | University Of Maryland, Baltimore | Aldh2 inhibitors and methods of use thereof |
| US20230399299A1 (en) | 2022-06-14 | 2023-12-14 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
| WO2023244584A1 (en) | 2022-06-14 | 2023-12-21 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU162377B (de) * | 1970-05-27 | 1973-02-28 | ||
| US4166862A (en) * | 1971-05-25 | 1979-09-04 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Animal feed containing anabolic isoflavones |
| GB8626344D0 (en) * | 1986-11-04 | 1986-12-03 | Zyma Sa | Bicyclic compounds |
| US5204369A (en) * | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
| AU3899199A (en) * | 1998-05-12 | 1999-11-29 | Endowment for Research in Human Biology, Inc., The | Methods and assays useful in the treatment of alcohol dependence or alcohol abuse |
| WO2004001058A2 (en) * | 2001-05-04 | 2003-12-31 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
| AUPR957001A0 (en) * | 2001-12-19 | 2002-01-24 | Novogen Research Pty Ltd | Isoflavone conjugates, derivatives thereof and therapeutic methods involving same |
| CA2491089A1 (en) * | 2002-06-27 | 2004-01-08 | The Endowment For Research In Human Biology, Inc. | Compounds useful for the inhibition of aldh |
| JP2008504292A (ja) * | 2004-06-24 | 2008-02-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 免疫増強用の化合物 |
| PL377180A1 (pl) * | 2005-09-21 | 2007-04-02 | Instytut Farmaceutyczny | Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz |
| EP2046769A2 (de) * | 2006-07-27 | 2009-04-15 | Cv Therapeutics, Inc. | Aldh-2-hemmer für die suchtbehandlung |
| RU2010122970A (ru) * | 2007-11-06 | 2011-12-20 | Си Ви Терапьютикс, Инк. (Us) | Ингибиторы aldh-2 при лечении психиатрических расстройств |
-
2008
- 2008-01-24 JP JP2010544284A patent/JP2011510072A/ja active Pending
- 2008-01-24 MX MX2010008111A patent/MX2010008111A/es not_active Application Discontinuation
- 2008-01-24 CN CN200880125439XA patent/CN101925590A/zh active Pending
- 2008-01-24 CA CA2712750A patent/CA2712750A1/en not_active Abandoned
- 2008-01-24 AU AU2008348372A patent/AU2008348372A1/en not_active Abandoned
- 2008-01-24 KR KR1020107016579A patent/KR20100130589A/ko not_active Application Discontinuation
- 2008-01-24 BR BRPI0822129-4A patent/BRPI0822129A2/pt not_active IP Right Cessation
- 2008-01-24 EP EP08713963A patent/EP2254878A1/de not_active Withdrawn
- 2008-01-24 WO PCT/US2008/051862 patent/WO2009094028A1/en active Application Filing
-
2010
- 2010-07-02 ZA ZA2010/04671A patent/ZA201004671B/en unknown
- 2010-07-21 IL IL207127A patent/IL207127A0/en unknown
- 2010-08-23 EC EC2010010417A patent/ECSP10010417A/es unknown
- 2010-08-23 MA MA33106A patent/MA32095B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009094028A1 (en) | 2009-07-30 |
| AU2008348372A1 (en) | 2009-07-30 |
| BRPI0822129A2 (pt) | 2015-06-23 |
| MX2010008111A (es) | 2010-11-30 |
| CA2712750A1 (en) | 2009-07-30 |
| JP2011510072A (ja) | 2011-03-31 |
| ZA201004671B (en) | 2011-03-30 |
| KR20100130589A (ko) | 2010-12-13 |
| IL207127A0 (en) | 2010-12-30 |
| ECSP10010417A (es) | 2010-11-30 |
| EP2254878A1 (de) | 2010-12-01 |
| CN101925590A (zh) | 2010-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA32095B1 (fr) | Inhibiteurs d'aldh-2 dans le traitement d'une accoutumance | |
| MA30434B1 (fr) | Inhibiteurs d'aldh-2 utilises pour le traitement d'une accoutumance | |
| MA35404B1 (fr) | Composés pour le traitement de la toxicomanie | |
| MA32684B1 (fr) | Dérivés de picolinamide en tant qu'inhibiteurs de kinase | |
| MA30228B1 (fr) | Pipéridinoylpyrrolidines agonistes du récepteur de mélanocortine de type 4 | |
| MA28077A1 (fr) | Derives d'isoquinilone 1,4-disubstitues en tant qu'inhibiteurs de raf-kinase utiles pour le traitement de maladies proliferantes | |
| MA31574B1 (fr) | Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf | |
| MA31084B1 (fr) | Derives de piperidine agonistes de gpcr | |
| TN2009000428A1 (fr) | Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale | |
| MA33836B1 (fr) | Compositions pharmaceutiques contenant des ligands des récepteurs sigma | |
| MA32232B1 (fr) | Nouveaux compoés hétérocycliques et leurs utilisations | |
| MA30351B1 (fr) | Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation | |
| MA33737B1 (fr) | Dérivés de glycoside et utilisations de ceux-ci | |
| MA29915B1 (fr) | Benzimidazoles substitues utilises en tant qu'inhibiteurs de kinases | |
| MA30394B1 (fr) | Synthese d'acylaminoalcenylene-amides pouvant etre employes en tant qu'antagonistes de la substance p | |
| MA33072B1 (fr) | Composes pyridazinone | |
| MA32171B1 (fr) | Compose heterocyclique | |
| MA32903B1 (fr) | Inhibiteurs de proteine-kinases | |
| MA38170B1 (fr) | Nouveaux acides indanyloxydihydrobenzofuranylacétiques | |
| MA34342B1 (fr) | Dérivés de la pipéridinone en tant qu'inhibiteurs de mdm2 pour le traitement du cancer | |
| MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
| MA30916B1 (fr) | Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine | |
| MA30762B1 (fr) | Anticorps specifiques du prlr et leurs utilisations | |
| MA30607B1 (fr) | N-phenylmethyl -5-oxo-proline-2-amides substitues tenant lieu d'antagonistes du recepteur p2x7 et procedes d'utilisation | |
| TN2009000138A1 (fr) | Biaryl-ether-urees |